BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 27378835)

  • 1. Monitoring of Tumor Growth with [(18)F]-FET PET in a Mouse Model of Glioblastoma: SUV Measurements and Volumetric Approaches.
    Holzgreve A; Brendel M; Gu S; Carlsen J; Mille E; Böning G; Mastrella G; Unterrainer M; Gildehaus FJ; Rominger A; Bartenstein P; Kälin RE; Glass R; Albert NL
    Front Neurosci; 2016; 10():260. PubMed ID: 27378835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrated analysis of dynamic FET PET/CT parameters, histology, and methylation profiling of 44 gliomas.
    Röhrich M; Huang K; Schrimpf D; Albert NL; Hielscher T; von Deimling A; Schüller U; Dimitrakopoulou-Strauss A; Haberkorn U
    Eur J Nucl Med Mol Imaging; 2018 Jul; 45(9):1573-1584. PubMed ID: 29732524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repeatability of Quantitative 18F-FET PET in Glioblastoma.
    Ferjančič P; Ebert MA; Francis R; Nowak AK; Jeraj R
    Biomed Phys Eng Express; 2021 Apr; 7(3):. PubMed ID: 33887712
    [No Abstract]   [Full Text] [Related]  

  • 4. Impact of partial volume effect correction on cerebral β-amyloid imaging in APP-Swe mice using [(18)F]-florbetaben PET.
    Brendel M; Delker A; Rötzer C; Böning G; Carlsen J; Cyran C; Mille E; Gildehaus FJ; Cumming P; Baumann K; Steiner H; Haass C; Herms J; Bartenstein P; Rominger A
    Neuroimage; 2014 Jan; 84():843-53. PubMed ID: 24055703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the amino acid tracers 18F-FET and 18F-DOPA in high-grade glioma patients.
    Lapa C; Linsenmann T; Monoranu CM; Samnick S; Buck AK; Bluemel C; Czernin J; Kessler AF; Homola GA; Ernestus RI; Löhr M; Herrmann K
    J Nucl Med; 2014 Oct; 55(10):1611-6. PubMed ID: 25125481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of Dexamethasone on O-(2-[
    Stegmayr C; Stoffels G; Kops ER; Lohmann P; Galldiks N; Shah NJ; Neumaier B; Langen KJ
    Mol Imaging Biol; 2019 Feb; 21(1):168-174. PubMed ID: 29845426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Point Spread Function Reconstruction for Integrated 18F-FET PET/MRI in Patients With Glioma: Does It Affect SUVs and Respective Tumor-to-Background Ratios?
    Rogasch JMM; Albers J; Steinkrüger FL; Lukas M; Wedel F; Amthauer H; Furth C
    Clin Nucl Med; 2019 Apr; 44(4):e280-e285. PubMed ID: 30562198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological tumour volumes of gliomas in early and standard 20-40 min
    Unterrainer M; Winkelmann I; Suchorska B; Giese A; Wenter V; Kreth FW; Herms J; Bartenstein P; Tonn JC; Albert NL
    Eur J Nucl Med Mol Imaging; 2018 Jul; 45(7):1242-1249. PubMed ID: 29487977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Value of O-(2-[18F]fluoroethyl)- L-tyrosine PET for the diagnosis of recurrent glioma.
    Pöpperl G; Götz C; Rachinger W; Gildehaus FJ; Tonn JC; Tatsch K
    Eur J Nucl Med Mol Imaging; 2004 Nov; 31(11):1464-70. PubMed ID: 15248032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. O-(2-[(18)F]fluoroethyl)-L-tyrosine uptake is an independent prognostic determinant in patients with glioma referred for radiation therapy.
    Sweeney R; Polat B; Samnick S; Reiners C; Flentje M; Verburg FA
    Ann Nucl Med; 2014 Feb; 28(2):154-62. PubMed ID: 24272067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PSMA PET Imaging in Glioblastoma: A Preclinical Evaluation and Theranostic Outlook.
    Kirchner MA; Holzgreve A; Brendel M; Orth M; Ruf VC; Steiger K; Pötter D; Gold L; Unterrainer M; Mittlmeier LM; Barci E; Kälin RE; Glass R; Lindner S; Kaiser L; Maas J; von Baumgarten L; Ilhan H; Belka C; Notni J; Bartenstein P; Lauber K; Albert NL
    Front Oncol; 2021; 11():774017. PubMed ID: 34869017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of blood-brain barrier permeability on O-(2-
    Stegmayr C; Bandelow U; Oliveira D; Lohmann P; Willuweit A; Filss C; Galldiks N; Lübke JH; Shah NJ; Ermert J; Langen KJ
    Eur J Nucl Med Mol Imaging; 2017 Mar; 44(3):408-416. PubMed ID: 27613541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delineation and agreement of FET PET biological volumes in glioblastoma: results of the nuclear medicine credentialing program from the prospective, multi-centre trial evaluating FET PET In Glioblastoma (FIG) study-TROG 18.06.
    Barry N; Francis RJ; Ebert MA; Koh ES; Rowshanfarzad P; Hassan GM; Kendrick J; Gan HK; Lee ST; Lau E; Moffat BA; Fitt G; Moore A; Thomas P; Pattison DA; Akhurst T; Alipour R; Thomas EL; Hsiao E; Schembri GP; Lin P; Ly T; Yap J; Kirkwood I; Vallat W; Khan S; Krishna D; Ngai S; Yu C; Beuzeville S; Yeow TC; Bailey D; Cook O; Whitehead A; Dykyj R; Rossi A; Grose A; Scott AM
    Eur J Nucl Med Mol Imaging; 2023 Nov; 50(13):3970-3981. PubMed ID: 37563351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utilizing 18F-fluoroethyltyrosine (FET) positron emission tomography (PET) to define suspected nonenhancing tumor for radiation therapy planning of glioblastoma.
    Hayes AR; Jayamanne D; Hsiao E; Schembri GP; Bailey DL; Roach PJ; Khasraw M; Newey A; Wheeler HR; Back M
    Pract Radiat Oncol; 2018; 8(4):230-238. PubMed ID: 29730279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of dynamic 18F-FET PET in newly diagnosed astrocytic high-grade glioma.
    Jansen NL; Suchorska B; Wenter V; Schmid-Tannwald C; Todica A; Eigenbrod S; Niyazi M; Tonn JC; Bartenstein P; Kreth FW; la Fougère C
    J Nucl Med; 2015 Jan; 56(1):9-15. PubMed ID: 25537990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. (68)Ga-Pentixafor-PET/CT for Imaging of Chemokine Receptor 4 Expression in Glioblastoma.
    Lapa C; Lückerath K; Kleinlein I; Monoranu CM; Linsenmann T; Kessler AF; Rudelius M; Kropf S; Buck AK; Ernestus RI; Wester HJ; Löhr M; Herrmann K
    Theranostics; 2016; 6(3):428-34. PubMed ID: 26909116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18F-FET microPET and microMRI for anti-VEGF and anti-PlGF response assessment in an orthotopic murine model of human glioblastoma.
    Nedergaard MK; Michaelsen SR; Urup T; Broholm H; El Ali H; Poulsen HS; Stockhausen MT; Kjaer A; Lassen U
    PLoS One; 2015; 10(2):e0115315. PubMed ID: 25680186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic impact of postoperative, pre-irradiation (18)F-fluoroethyl-l-tyrosine uptake in glioblastoma patients treated with radiochemotherapy.
    Piroth MD; Holy R; Pinkawa M; Stoffels G; Kaiser HJ; Galldiks N; Herzog H; Coenen HH; Eble MJ; Langen KJ
    Radiother Oncol; 2011 May; 99(2):218-24. PubMed ID: 21497925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. O-(2-[18F]fluoroethyl)-L-tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma.
    Pöpperl G; Goldbrunner R; Gildehaus FJ; Kreth FW; Tanner P; Holtmannspötter M; Tonn JC; Tatsch K
    Eur J Nucl Med Mol Imaging; 2005 Sep; 32(9):1018-25. PubMed ID: 15877226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. O-(2-
    Imperiale A; Boisson F; Kreutter G; Goichot B; Namer IJ; Bachellier P; Laquerriere P; Kessler L; Marchand P; Brasse D
    Nucl Med Biol; 2017 Oct; 53():21-28. PubMed ID: 28793277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.